NASDAQ:TVGN

Tevogen Bio 8/19/2025 Earnings Results & Report

Tevogen Bio logo
$5.69 -0.53 (-8.52%)
Closing price 11/17/2026 03:53 PM Eastern
Extended Trading
$5.74 +0.04 (+0.79%)
As of 07:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tevogen Bio beat analyst earnings expectations in results released August 19, 2025. The company reported EPS of -$1.50 versus the -$2.50 consensus estimate.

Earnings Announcement Details

Report Date
Time
Before Market Opens

Tevogen Bio EPS Results

Actual EPS
-$1.50
Consensus EPS
-$2.50
Beat/Miss
Beat by +$1.00
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 5 quarters

Tevogen Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Tevogen Bio Earnings FAQ

Tevogen Bio (NASDAQ:TVGN) reported earnings of -$1.50 per share for the quarter, beating the consensus estimate of -$2.50. The report was announced on Tuesday, August 19, 2025.

Tevogen Bio Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
Tevogen Bio Holdings Rebrands as Tevogen Inc.
See More Tevogen Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tevogen Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tevogen Bio and other key companies, straight to your email.

About Tevogen Bio

Tevogen Bio (NASDAQ:TVGN) is a clinical-stage biotechnology company developing cell-based immunotherapies. Its ExacTcell platform uses donor-derived, antigen-specific T cells designed to recognize and attack disease-associated targets, with the goal of making therapies available without creating a custom treatment for each patient.

The company’s lead investigational candidate, TVGN 489, is a T-cell therapy being developed for COVID-19. Tevogen is also pursuing potential applications of its platform in cancer and other diseases. Its candidates remain investigational and are not approved treatments.

Founded by physician and health economist Ryan Saadi, who serves as the company’s chief executive officer, Tevogen became a publicly traded company in 2024 through a merger with Semper Paratus Acquisition Corporation. The company is based in Warren, New Jersey.

View Tevogen Bio Profile